Pharmaceutical - UK, AstraZeneca

Filter

Current filters:

UKAstraZeneca

Popular Filters

1 to 25 of 40 results

FDA accepts NDA filing from AstraZeneca for Iressa

FDA accepts NDA filing from AstraZeneca for Iressa

02-12-2014

The US Food and Drug Administration has accepted for filing the New Drug Application from Iressa (gefitinib)…

AstraZenecaIressaOncologyPharmaceuticalRegulationUK

AstraZeneca signs drug discovery collaboration with Cancer Research UK

AstraZeneca signs drug discovery collaboration with Cancer Research UK

28-11-2014

UK pharma major AstraZeneca and charity Cancer Research UK have signed a memorandum of understanding…

AstraZenecaOncologyPharmaceuticalResearchUK

MHRA showcases benefit of its industry collaboration with AstraZeneca's Macclesfield plant

MHRA showcases benefit of its industry collaboration with AstraZeneca's Macclesfield plant

27-11-2014

The UK's Medicines and Healthcare products Regulatory Agency has published a case study outlining the…

AstraZenecaOncologyPharmaceuticalProductionUK

AstraZeneca’s Duaklir Genuair approved in the EU for COPD

AstraZeneca’s Duaklir Genuair approved in the EU for COPD

25-11-2014

The European Commission has granted marketing authorization for Anglo-Swedish pharma major AstraZeneca’s…

AstraZenecaDuaklir GenuairPharmaceuticalRegulationRespiratory and PulmonaryUK

European prescribing trends for mCR prostate cancer

20-11-2014

Johnson & Johnson/AstraZeneca’s Zytiga (abiraterone acetate) is the clear agent of choice for second-line…

Astellas PharmaAstraZenecaBayerDendreonFranceGermanyItalyJohnson & JohnsonMarkets & MarketingMedivationOncologyPharmaceuticalProvengeSpainUKXofigoXtandiZytiga

AstraZeneca reinforces target of $45 billion revenues by 2023

AstraZeneca reinforces target of $45 billion revenues by 2023

18-11-2014

Anglo-Swedish pharma major AstraZeneca today provided an update for institutional investors and financial…

AstraZenecaCardio-vascularFinancialInflammatory diseasesMetabolicsOncologyPharmaceuticalRespiratory and PulmonaryUK

SMC accepts Eylea and Onglyza for use in NHS Scotland

SMC accepts Eylea and Onglyza for use in NHS Scotland

13-11-2014

The Scottish Medicines Consortium (SMC) has accepted German drugmaker Bayer’s Eylea (aflibercept solution…

AstraZenecaBayerDiabetesEyleaOnglyzaPharmaceuticalRegulationUK

AstraZeneca and University of Glasgow partner to form immunology discovery center

AstraZeneca and University of Glasgow partner to form immunology discovery center

04-11-2014

The University of Glasgow and Anglo-Swedish drug major AstraZeneca have now officially launched the GLAZgo…

AstraZenecaImmunologicalsPharmaceuticalResearchUK

AstraZeneca partners with Manchester University on improving drug delivery and efficacy

AstraZeneca partners with Manchester University on improving drug delivery and efficacy

30-10-2014

Anglo-Swedish drug major AstraZeneca has entered into a strategic collaboration with the University of…

AstraZenecaHealth Medical PharmaPharmaceuticalResearchUK

Neuroscience a key feature of AstraZeneca’s collaboration with University of Cambridge

Neuroscience a key feature of AstraZeneca’s collaboration with University of Cambridge

16-10-2014

Anglo-Swedish drug major AstraZeneca, together with its global biologics R&D arm MedImmune, has entered…

AstraZenecaNeurologicalPharmaceuticalResearchUK

ESMO 2014: AstraZeneca’s AZD9291 and Iressa

ESMO 2014: AstraZeneca’s AZD9291 and Iressa

01-10-2014

The annual congress of the European Society for Medical Oncology (ESMO) came to a close in Madrid, Spain,…

AstraZenecaAZD9291IressaOncologyPharmaceuticalResearchUK

EASD 2014: AstraZeneca highlights range of choice in its diabetes portfolio

EASD 2014: AstraZeneca highlights range of choice in its diabetes portfolio

29-09-2014

Diabetes is a firm priority of UK-based pharma major AstraZeneca and is in no danger of being side-lined,…

AstraZenecaBydureonDiabetesForxigaInterviewsOnglyzaPharmaceuticalResearchUK

AstraZeneca’s Byetta meets primary endpoint in diabetes trial and reduces weight

AstraZeneca’s Byetta meets primary endpoint in diabetes trial and reduces weight

24-09-2014

UK-based pharma major AstraZeneca has announced new research showing that Byetta (exenatide) added to…

AstraZenecaByettaDiabetesGlucagonPharmaceuticalResearchUK

Lilly to pay up to $500 million for AstraZeneca Alzheimer’s candidate

Lilly to pay up to $500 million for AstraZeneca Alzheimer’s candidate

16-09-2014

Anglo-Swedish pharma major AstraZeneca and US peer Eli Lilly have entered an agreement to jointly develop…

AstraZenecaAZD3293Eli LillyLicensingNeurologicalPharmaceuticalResearchUKUSA

Pfizer could try to acquire Actavis as back-up to a further bid for AstraZeneca

Pfizer could try to acquire Actavis as back-up to a further bid for AstraZeneca

22-08-2014

While speculation continues as to whether Pfizer will resume its attempts to buy AstraZeneca, Pfizer…

ActavisAstraZenecaBusiness FinanceIrelandMergers & AcquisitionsPfizerPharmaceuticalSwedenUKUnited StatesUSA

US DoJ closes investigation into AstraZeneca’s PLATO trial for Brilinta

US DoJ closes investigation into AstraZeneca’s PLATO trial for Brilinta

19-08-2014

Anglo-Swedish drug major AstraZeneca has received confirmation from the US Department of Justice that…

AstraZenecaBrilintaBrilintaCardio-vascularLegalPharmaceuticalUKUSA

NICE comes back with different views on Tarceva and Iressa for NSCLC

NICE comes back with different views on Tarceva and Iressa for NSCLC

07-08-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) is consulting again…

AstraZenecaIressaOncologyPharmaceuticalPricingRegulationRocheTarcevaUK

AstraZeneca 2nd-qtr earnings leap, beating expectations

AstraZeneca 2nd-qtr earnings leap, beating expectations

31-07-2014

Anglo-Swedish pharma major AstraZeneca, which earlier this year defended itself against an unsolicited…

AstraZenecaBusiness FinanceFinancialPharmaceuticalUK

AstraZeneca and Kyowa Hakko Kirin sign immunotherapy research deal

AstraZeneca and Kyowa Hakko Kirin sign immunotherapy research deal

30-07-2014

Anglo-Swedish pharma major AstraZeneca today announced that it has entered into a clinical study collaboration…

AstraZenecaBriggs MorrisonImmunologyJapanKyowa Hakko KirinOncologyPharmaceuticalResearchUK

Pharmaceuticals, a strategic sector for the UK government

Pharmaceuticals, a strategic sector for the UK government

28-07-2014

Britain’s pharmaceuticals sector, which includes AstraZeneca and GlaxoSmithKline, two drugmakers among…

AstraZenecaEconomy of the United KingdomFinancialGlaxoSmithKlineMarkets & MarketingPharmaceuticalResearchUK

Seven pharma companies offer up compounds to UK researchers

Seven pharma companies offer up compounds to UK researchers

22-07-2014

UK researchers will be granted access to a ‘virtual library’ of deprioritized pharmaceutical compounds…

AstraZenecaEli LillyGlaxoSmithKlineJanssenMedical Research CouncilPfizerPharmaceuticalResearchTakeda PharmaceuticalUCBUK

AstraZeneca reveals designs for new global R&D center and HQ in Cambridge, UK

AstraZeneca reveals designs for new global R&D center and HQ in Cambridge, UK

20-07-2014

Anglo-Swedish pharma major AstraZeneca on Friday revealed designs for its planned network of glass-walled…

AstraZenecaManagementPharmaceuticalResearchUK

AstraZeneca’s Bydureon controls diabetes better than insulin glargine

AstraZeneca’s Bydureon controls diabetes better than insulin glargine

30-05-2014

Anglo-Swedish pharma major AstraZeneca has announced that Bydureon (exenatide once-weekly injection)…

Anti-diabetic drugsAstraZenecaBydureonDiabetesGlucagonPharmaceuticalResearchUK

1 to 25 of 40 results

COMPANY SPOTLIGHT

Parexel

Parexel

Back to top